How Is Traditional Wegovy Administered?
Wegovy is semaglutide, a GLP-1 receptor agonist for weight loss and obesity management. The standard form is a once-weekly subcutaneous injection using a pre-filled pen. Doses start at 0.25 mg and escalate to 2.4 mg over 16 weeks.[1]
What Is the New Wegovy Pill?
The "new Wegovy pill" refers to an oral semaglutide formulation Novo Nordisk is developing as an oral version of Wegovy. Unlike the injectable, it is taken daily. It uses the same active ingredient but requires higher doses due to lower bioavailability—early trials tested up to 50 mg daily versus 2.4 mg weekly for the injection.[2][3]
Key Differences in Delivery and Use
| Aspect | Injectable Wegovy | Oral Wegovy (in development) |
|-----------------|------------------------------------|-----------------------------------|
| Frequency | Once weekly | Once daily |
| Method | Subcutaneous injection | Swallowed tablet (on empty stomach) |
| Dose | 0.25–2.4 mg weekly | Up to 50 mg daily |
| Convenience| Requires needles; self-injected | No needles; pill form |
| Absorption | High bioavailability (~89%) | Lower (~1%); needs stomach acid protection |
| Approval Status | FDA-approved since 2021 for weight loss | Phase 3 trials ongoing; not approved as Wegovy yet (related oral semaglutide approved as Rybelsus for diabetes) [1][2] |
The oral version aims to match weight loss efficacy (15–20% body weight reduction in trials) but faces challenges like gastrointestinal side effects from daily dosing.[3]
Effectiveness and Clinical Data Comparison
Both forms drive weight loss by mimicking GLP-1 to reduce appetite and slow gastric emptying. Head-to-head data is limited, but oral semaglutide in obesity trials (OASIS 1) showed 15% weight loss at 68 weeks on 50 mg daily, comparable to injectables. Injections may edge out on adherence due to weekly dosing.[3][4]
Side Effects and Patient Considerations
Common side effects overlap: nausea, diarrhea, vomiting (50–70% of users). Oral version may worsen GI issues due to daily intake and food restrictions (take 30+ minutes before eating). Injections cause fewer peak side effects. Cost and insurance coverage similar once approved; injections currently ~$1,300/month without coverage.[1][2]
When Will the Pill Be Available?
Phase 3 results expected 2025; Novo Nordisk plans regulatory submission soon after. Not yet approved for obesity as Wegovy—distinct from Rybelsus (daily 3–14 mg for diabetes only).[3]
Sources
[1] Wegovy.com
[2] FDA.gov (Semaglutide Info)
[3] Novo Nordisk Press Release (OASIS Trials)
[4] NEJM (Semaglutide Weight Loss Trials)